{"doi":"10.1002/cam4.4260","title":"Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety","abstract":"BACKGROUND: The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum-based chemotherapy and baseline disease. METHODS: Patients were randomized 2:1 to receive either oral rucaparib at a dosage of 600 mg twice daily or placebo. Investigator-assessed PFS was assessed in prespecified, nested cohorts: BRCA-mutated, homologous recombination deficient (HRD; BRCA mutated or wild-type BRCA/high loss of heterozygosity), and the intent-to-treat (ITT) population. RESULTS: Median PFS for patients in the ITT population with a complete response to most recent platinum-based chemotherapy was 11.1 months in the rucaparib arm (126 patients) versus 5.6 months in the placebo arm (64 patients) (HR, 0.33 [95% CI, 0.23-0.48]), and in patients with a partial response (249 vs. 125), it was 9.0 versus 5.3 months (HR, 0.38 [0.30-0.49]). In subgroups of the ITT population based on baseline disease, median PFS was 8.2 versus 5.3 months (HR, 0.40 [0.28-0.57]) in patients with measurable disease (141 rucaparib vs. 66 placebo), 10.4 versus 4.5 months (HR, 0.31 [0.20-0.48]) in those with nonmeasurable but evaluable disease (104 vs. 56), and 14.1 versus 7.3 months (HR, 0.35 [0.24-0.51]) in those with no residual disease (130 vs. 67). Across subgroups, significantly longer median PFS was observed with rucaparib versus placebo in the BRCA-mutated and HRD cohorts. Objective responses were reported in patients with measurable disease and in patients with nonmeasurable but evaluable baseline disease. Safety was consistent across subgroups. CONCLUSION: Rucaparib maintenance treatment provided clinically meaningful efficacy benefits across subgroups based on response to last platinum-based chemotherapy or baseline disease.","journal":"Cancer Medicine","year":2021,"id":206300,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9449,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":258139,"name":"Amit M. Oza","orcid":"0000-0002-9510-8641","position":1,"is_corresponding":false},{"id":406831,"name":"Domenica Lorusso","orcid":"0000-0003-0981-0598","position":2,"is_corresponding":false},{"id":258142,"name":"Carol Aghajanian","orcid":"0000-0003-0851-3225","position":3,"is_corresponding":false},{"id":406833,"name":"Andrew Dean","orcid":"0000-0001-6632-2799","position":4,"is_corresponding":false},{"id":50716,"name":"Nicoletta Colombo","orcid":"0000-0003-2225-715X","position":5,"is_corresponding":false},{"id":406834,"name":"Johanne I. Weberpals","orcid":"0000-0002-0355-547X","position":6,"is_corresponding":false},{"id":258151,"name":"Andrew R. Clamp","orcid":"0000-0002-4200-0186","position":7,"is_corresponding":false},{"id":315599,"name":"Giovanni Scambia","orcid":"0000-0002-9503-9041","position":8,"is_corresponding":false},{"id":406835,"name":"Alexandra Léary","orcid":"0000-0002-2043-2244","position":9,"is_corresponding":false},{"id":406836,"name":"Robert W. Holloway","orcid":"0000-0002-3121-4605","position":10,"is_corresponding":false},{"id":406837,"name":"Margarita Amenedo","orcid":"0009-0002-2756-831X","position":11,"is_corresponding":false},{"id":89423,"name":"Peter C.C. Fong","orcid":"0000-0003-2689-8958","position":12,"is_corresponding":false},{"id":406838,"name":"Jeffrey C. Goh","orcid":"0000-0003-3103-146X","position":13,"is_corresponding":false},{"id":258149,"name":"David M. O’Malley","orcid":"0000-0002-2828-0177","position":14,"is_corresponding":false},{"id":62906,"name":"Deborah K. Armstrong","orcid":"0000-0003-0852-803X","position":15,"is_corresponding":false},{"id":33574,"name":"Susana Banerjee","orcid":"0000-0002-8840-7934","position":16,"is_corresponding":false},{"id":33528,"name":"Jesús García-Donás","orcid":"0000-0001-7731-3601","position":17,"is_corresponding":false},{"id":70261,"name":"Elizabeth M. Swisher","orcid":"0000-0003-2331-0434","position":18,"is_corresponding":false},{"id":408064,"name":"T. Cameron","orcid":null,"position":19,"is_corresponding":false},{"id":408065,"name":"Lara Maloney","orcid":null,"position":20,"is_corresponding":false},{"id":408066,"name":"Sandra Goble","orcid":null,"position":21,"is_corresponding":false},{"id":406840,"name":"Jonathan A. Ledermann","orcid":"0000-0003-3799-3539","position":22,"is_corresponding":false},{"id":258137,"name":"Robert L. Coleman","orcid":"0000-0001-9343-8754","position":23,"is_corresponding":false},{"id":406832,"name":"Ana Oaknin","orcid":"0000-0002-3592-7194","position":0,"is_corresponding":true}],"reference_count":19,"raw_metadata":null,"created_at":"2026-07-18T23:51:37.630221Z","pmid":"34549539","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}